Amneal Pharmaceuticals, Inc.
AMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001723128
No open-market purchases or sales by Amneal Pharmaceuticals, Inc. insiders were filed in the last 90 days; 312 institutions reported holding it in 13F filings for Q2 2026, worth $2.82B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $7.45B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 312
- 13F valueReported value at the end of Q2 2026
- $2.82B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $3.02B
- +8.0% year over year
- Net income, FY2025
- $72.1M
- No comparable prior period
- Free cash flow, FY2025
- $269.9M
- +11.0% year over year
- Revenue, Q3 FY2026
- $862.7M
- +10.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.4M
- Shares sold short
- Change
- −2.68M
- −19.0% vs. previous
- Days to cover
- 2.79
- At average daily volume
Superinvestors holding AMRX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AMRX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Amneal Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 (view filing)4:29 PM ET | Aug 13 | 1 day | Kiely JohnDirector | SSaleClass A Common Stock | −50.0K | $17.64 | −$882.0K | −19.2%210.3K after | |
| Aug 13, 2026 (view filing)4:22 PM ET | Aug 12 | 1 day | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −146.4K | $17.51 | −$2.56M | −36.6%253.4K after | |
| Aug 13, 2026 (view filing)4:21 PM ET | Aug 11-12 | 2 days | Daly Jason B.EVP, Chief Legal Officer | SSaleClass A Common Stock | −216.6K | $17.41 | −$3.77M | −86.0%35.2K after | 2 lots |
| May 12, 2026 (view filing) | May 11 | 1 day | Autor Deborah M.Director | SSaleClass A Common Stock | −34.8K | $12.94 | −$450.6K | −27.1%93.7K after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Nark Ted CDirector | SSaleClass A Common Stock | −50.0K | $11.72 | −$586.0K | −14.7%291.0K after | |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −131.9K | $11.92 | −$1.57M | −47.4%146.4K after | |
| Aug 28, 2025 (view filing) | Aug 27 | 1 day | Kiely JohnDirector | SSaleClass A Common Stock | −32.0K | $9.23 | −$295.4K | −12.4%225.4K after | |
| Aug 25, 2025 (view filing) | Aug 22-25 | 3 days | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −120.8K | $9.65 | −$1.17M | −45.2%146.4K after | 2 lots |
| Aug 22, 2025 (view filing) | Aug 20 | 2 days | Boyer Andrew SExecutive Vice President | SSaleClass A Common Stock | −279.2K | $9.38 | −$2.62M | −64.7%152.4K after | |
| Aug 15, 2025 (view filing) | Aug 14 | 1 day | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −71.7K | $9.29 | −$666.0K | −21.2%267.2K after |
Top 10 13F holders, Q2 2026
See all 312 holdersThe largest institutional positions in Amneal Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 26,562,093 | $459.8M | 0.01% | +2,042,901+8.3% | Added |
| TPG GP A, LLC | 12,328,767 | $213.4M | 4.27% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 12,137,727 | $210.1M | 0.01% | +812,794+7.2% | Added |
| Rubric Capital Management LP | 10,168,660 | $176.0M | 1.61% | −868,929−7.9% | Reduced |
| Vanguard Capital Management LLC | 7,710,126 | $133.5M | 0.00% | +125,092+1.6% | Added |
| State Street Corp | 7,356,977 | $127.3M | 0.00% | +562,275+8.3% | Added |
| Dimensional Fund Advisors LP | 5,794,263 | $100.3M | 0.02% | +103,677+1.8% | Added |
| Geode Capital Management, LLC | 5,139,449 | $89.0M | 0.00% | +593,401+13.1% | Added |
| Morgan Stanley | 4,110,028 | $71.1M | 0.00% | −527,157−11.4% | Reduced |
| Neuberger Berman Group LLC | 3,887,179 | $67.3M | 0.04% | +204,895+5.6% | Added |
Holders of 5% or more of AMRX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Amneal Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Patel Tushar Bhikhubhai | 13D/A | 17.60%61.3M shares | +1.90 ppfrom 15.70% | Oct 18, 20235 filings | Aug 12, 2026 | SEC |
| Patel Chintu | 13D/A | 9.40%32.6M shares | +1.20 ppfrom 8.20% | Oct 18, 20234 filings | Aug 12, 2026 | SEC |
| Patel Chirag K. | 13D/A | 8.40%29.1M shares | +1.30 ppfrom 7.10% | Oct 18, 20235 filings | Aug 12, 2026 | SEC |
| BlackRock, Inc. | 13G | 7.60%24.1M shares | New | Apr 27, 20261 filing | Apr 27, 2026 | SEC |
| Mahesh Akram | 13G/A | 6.56%20.6M shares | – | Jan 5, 20243 filings | May 14, 2025 | SEC |